



PCT/AU2004/001423

Patent Office  
Canberra

I, LEANNE MYNOTT, MANAGER EXAMINATION SUPPORT AND SALES hereby certify that annexed is a true copy of the Provisional specification in connection with Application No. 2003905642 for a patent by VIP DEVELOPMENT PTY LTD as filed on 15 October 2003.


I further certify that the name of the applicant has been amended to VIRAX DEVELOPMENT PTY LTD pursuant to the provisions of Section 104 of the Patents Act 1990.

BEST AVAILABLE COPY

WITNESS my hand this  
First day of November 2004

A handwritten signature in black ink, appearing to be 'LM' or similar, written over a horizontal line.

LEANNE MYNOTT  
MANAGER EXAMINATION SUPPORT  
AND SALES



Regulation 3.2

**A U S T R A L I A**  
**Patents Act 1990**

**PROVISIONAL SPECIFICATION**

for the invention entitled:

**"A viral vector and methods of using same"**

**The invention is described in the following statement:**

- 1 -

## A VIRAL VECTOR AND METHODS OF USING SAME

### BACKGROUND OF THE INVENTION

#### 5 FIELD OF THE INVENTION

The present invention relates generally to a recombinant vector and its use in the treatment and/or prophylaxis of retroviral infections and the symptoms associated therewith. More particularly, the present invention provides a recombinant vector for  
10 use in conjunction with anti-retroviral drug treatment (ARDT) to modulate viral load in a subject. The present invention specifically relates to a recombinant poxvirus vector expressing a retrovirus antigen and/or a modulatory factor and its use in conjunction with anti-HIV retroviral drug therapy in the treatment or prophylaxis of HIV infection, AIDS and AIDS-related disorders in a human subject. The vectors and methods of the  
15 present invention are particularly useful in preventing, reducing or delaying viral rebound when retroviral therapy is interrupted.

#### 20 DESCRIPTION OF THE PRIOR ART

Bibliographic details of the references in this specification are collected at the end of the description.

Reference to any prior art in the specification is not, and should not be taken as, an  
25 acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.

Retroviruses are obligate intracellular parasites of vertebrate cells. Viral propagation of the enveloped RNA virus is via a double stranded DNA provirus intermediate which  
30 integrates into the genomic DNA of a susceptible host cell and makes use of many host cell factors. This efficient system of infection and propagation makes eradication of the virus very difficult. It is estimated that HIV replication in an infected individual can

- 2 -

involve the production and clearance of 10 billion virions per day, each virion having a half-life of about six hours in the general circulation (Australian Society for HIV Medicine (ASHM)-2001 Australian Antiretroviral Guidelines).

- 5 All retrovirus genomes comprise three major coding domains: *gag*, which is responsible for matrix, capsid and nucleoprotein structures; *pol* which encodes an RNA-dependent DNA polymerase, reverse transcriptase, and also integrase enzymes; and *env* which generates viral envelope proteins. In addition, all retroviruses also comprise the *pro* coding domain responsible for producing virion protease. A subset of retroviruses termed
- 10 "complex" retroviruses also comprise a range of regulatory factors which influence their own and host expression pathways.

The retrovirus family includes Lentiviruses such as Human immunodeficiency virus (HIV-1 and HIV-2), Simian immunodeficiency virus (SIV), Human T-cell leukaemia-bovine

- 15 leukaemia viral group such as Human T-cell leukaemia virus (HTLV), Feline leukaemia virus (FIV) and Spumaviruses as described in Vogt P.K. (Chapter 1: *Retroviruses: Coffin John M et al (eds), Cold Spring Harbour Laboratory Press, USA, 1997*).

- 20 HIV is a particularly important complex retrovirus of humans as the causative agent of Acquired Immune Deficiency Syndrome (AIDS) which remains a devastating and complex problem despite recent advances in anti-retroviral drug treatments.

HIV infects CD4+ immune cells and established HIV infections are characteristically associated with progressive immune system damage, opportunistic infections and wasting

- 25 syndromes. Commencement of anti-retroviral therapy is generally recommended at any stage of HIV infection when immune deficiency is present as determined by, for example, low levels of CD4+ cells. Reductions in plasma viral load in response to anti-retroviral treatment are associated with statistically significant improvements in survival and clinical outcome (Melors J.W. *et al, Science* 272:1167-1170, 1996). Complete eradication of HIV
- 30 in a subject is presently considered to be an unrealistic goal, and as viral levels may

There are a large range of anti-retroviral drug treatment regimens involving the administration of combinations of anti-retroviral compounds (see for example ASHM-2001 draft Australian antiretroviral guidelines, *supra*). In particular, limited clinical data have indicated that triple therapy in the treatment of acute and advanced HIV infection employing a nucleoside analogue combination and a non-nucleoside reverse transcriptase inhibitor or protease inhibitor has a positive effect on surrogate markers of disease progression and at least a short term clinical benefit.

25 In view of the difficulties associated with anti-retroviral drug treatment there is an urgent  
need for greater understanding of the host-retrovirus interaction and to identify effective  
methods and reagents for controlling retroviral infections and improving current anti-  
retroviral drug treatment regimens particularly to facilitate their long term efficacy. Also,  
in view of the undesirable and often severe side-effects, there is a need for treatment  
30 protocols which allow periods in which anti-retroviral drugs are not administered. As a

- 4 -

result of the onerous and intrusive treatment regimens, there is a demand from patients for protocols which allow them periods in which they do not take anti-retroviral drugs.

## 5 SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the  
10 exclusion of any other element or integer or group of elements or integers.

Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO:). The SEQ ID NOs: correspond numerically to the sequence identifiers <400>1 (SEQ ID NO:1), <400>2 (SEQ ID NO:2), etc. A summary of sequence identifiers is  
15 provided in Table 1. A sequence listing is provided after the claims.

The present invention is predicated, in part, on the development of a vector which expresses a retrovirus antigen and/or a host modulatory factor and which upon administration to a subject is capable of reducing, preventing or delaying viral rebound or  
20 of reducing, preventing or delaying the increase or rate of increase in viral load in a subject. As there are significant disadvantages and difficulties with present anti-retroviral drug treatment regimens in terms of their efficacy, side effects and compliance, it is anticipated that the vectors of the present invention will find broad application in the treatment of retroviral infections in conjunction with anti-retroviral drug treatment.

25 In one aspect, the present vector is a poxvirus vector which expresses one or more antigens of HIV and/or a cytokine which vector is administered in conjunction with anti-retroviral drug therapy. In a preferred aspect the present invention provides a method for treatment or prophylaxis of one or more symptoms of retroviral infection such as HIV infection,  
30 comprising the administration of a poxvirus vector encoding a retrovirus antigen and/or a cytokine or a functional homolog, derivative, part or analog thereof, in conjunction with

- 5 -

anti-retroviral drug therapy wherein said polypeptide and/or cytokine are expressed in a subject and are effective in maintaining a low viral load in a subject for a period of time, for example effectively preventing, reducing or delaying viral rebound during interruption of anti-retroviral drug treatment. Methods are also provided for reducing or alleviating one or more of the side effects of ARDT comprising administering the instant vectors for a time and under conditions to reduce or alleviate one or more of the said effects of ARDT. The vectors may be administered before and/or during ARDT and/or after withdrawal of ARDT. In an exemplary embodiment, the vector is a fowlpox vector co-expressing gag/pol and IFN- $\gamma$  which effectively maintains a low viral vector load, or delays the increase in viral load when antiretroviral drug treatment is interrupted. The present invention extends to pharmaceutical agents comprising the vectors of the present invention and their use in a range of treatment regimens.

PROMOTIONS - 1/7/2003 - 12/15/2003 - 12/15/2003

- 6 -

A summary of sequence identifiers used throughout the subject specification is provided in Table 1.

**TABLE 1****Summary of sequence identifiers**

5

SEQUENCE ID NO.	NAME	DESCRIPTION
1		
2		
3		
4		



- 7 -

**BRIEF DESCRIPTION OF THE FIGURES**

5 **Figure 1 is a graphical representation showing the mean viral load (non-log) over the 20 week period of the extension trial for each vector recipient group. Subject Group A (white line) received the full construct (FC) comprising recombinant FPV expressing HIV-1 gag/pol and interferon-gamma (IFN $\gamma$ ). Subject Group B (black line) received the partial construct (PC) comprising recombinant FPV expressing HIV-1 gag/pol. Subject Group C (grey line) received diluent alone (placebo).**

10 **Figure 2 is a graphical representation showing the proportion of recipients in each recipient group whose viral load was low enough over the period of the study (in days) such that ARDT was not re-initiated. Subject Group A received the full construct (FC) comprising recombinant FPV expressing HIV-1 gag/pol and interferon-gamma (IFN $\gamma$ ).**  
15 **Subject Group B received the partial construct (PC) comprising recombinant FPV expressing HIV-1 gag/pol. Subject Group C received diluent alone (placebo).**

- 8 -

**DETAILED DESCRIPTION OF THE INVENTION**

5 The present invention provides a vector which effectively modulates retroviral load in a subject. Specifically, the vector of the present invention maintains or prolongs a low viral load in a subject infected with a retroviral infection. In a preferred aspect the vector of the present invention is used in conjunction with anti-retroviral drug therapy and is useful in maintaining a low viral load before, after or between periods of drug therapy.

10 In one aspect, the present invention provides a recombinant vector comprising a sequence of nucleotides encoding a retrovirus antigen and/or a sequence of nucleotides encoding a modulatory factor, or a functional homolog, derivative, part or analog thereof, which expresses said sequences for use in conjunction with ARDT in the treatment or prophylaxis of one or more symptoms associated with a retroviral infection in a subject.

15 Reference herein to anti-retroviral drug treatment (ARDT) is used in its broadest context to include the use of one or more compounds, singly or in combination in regimens for retroviral, and in particular HIV retroviral, treatment.

20 Anti-retroviral compounds act by a number of different of mechanisms which selectively affect the virus. For example, protease inhibitors, reverse transcriptase inhibitors and ribonucleotide reduction inhibitors may be employed or compounds which inhibit viral adsorption, assembly, integration and transcription. As will be known to those skilled in the art there are a large number of anti-retroviral compounds which may be administered.

25 Examples of protease inhibitors include Indinavir and Nelfinavir. Reverse transcriptase inhibitors include, for example, Zidovisidine, Stavudine and Didanosine. Examples of ribonucleotide reductase inhibitors include thiosemicarbazone derivatives.

30 The particular compounds and combinations used and the dosages and regimens will be determined by the administering practitioner and will depend *inter alia*, upon individual responses to the treatment.

- 9 -

In another aspect, the present invention provides a recombinant vector comprising a sequence of nucleotides encoding a retrovirus antigen and a sequence of nucleotides encoding a modulatory factor, or a functional homolog, derivative, part or analog thereof, which co-expresses said constituents for use in conjunction with ARDT in the treatment or prophylaxis of one or more symptoms associated with a retroviral infection in a subject.

As used herein the singular forms "a", "an" and "the" include plural aspects unless the context clearly dictates otherwise. Thus, for example, reference to a "compound" includes a single compound, as well as two or more compounds; reference to "an active agent" includes a single active agent, as well as two or more active agents; and so forth.

The term "antigen" is used in its broadest context to include molecules comprising one or more epitopes against which an immune response is produced. The term however, also includes within its scope any polypeptide, including a protein or peptide. Antigenic portions may be identified using well known techniques, such as those set out in Paul, Fundamental Immunology, 3<sup>rd</sup> Ed., 243-247 (Raven Press, 1993) and references cited therein.

The term "recombinant vector" is used herein in its broadest sense as a reference to constructs which are capable of vectoring or carrying nucleic acid molecules into a target cell for expression therein. The vectors of the present invention include viral vectors or similar constructs or derivatives thereof, plasmid vectors or naked nucleic acid molecules.

Poxvirus vectors are particularly convenient vectors. As used herein reference to "poxvirus" includes viruses selected from the group comprising avipox (eg, fowlpox, canarypox, pigeonpox) orthopox (eg, vaccinia) capripox (eg, shecp, goats) and suipox (eg, swinepox). Preferred poxvirus vectors are avipox or orthopox vectors. Avipox vectors are preferred vectors. A particularly preferred avipoxvirus vector is a fowlpox vector (FPV). Exemplary fowlpox vectors are FPV-M3 vectors as described in International Patent Publication No. WO 00/28003. The principles and procedures for

- 10 -

generating and using recombinant poxvirus vectors are well known in the art. Briefly, homologous recombination between a donor recombination vector and a poxvirus within a host cell permits correct introduction of the desired sequences.

- 5 Reference to "modulates" includes down regulations of viral load, maintenance of viral load and a change in the rate of increase of viral load. Specifically, any change in viral load is usually but not exclusively determined over an appropriate period of time and is expressed in terms of change in average viral load over time of a subject or group of subjects.

10

Accordingly, the present invention provides a recombinant poxvirus vector comprising a sequence of nucleotides encoding a retrovirus antigen and a sequence of nucleotides encoding a modulatory factor, or a functional homolog, derivative, part or analog thereof, which co-expresses said constituents for use in conjunction with ARDT in the treatment or

- 15 prophylaxis of one or more symptoms associated with a retroviral infection in a subject.

- Reference to "treatment" and "prophylaxis" are to be considered in their broadest context. The term treatment includes partial and full recovery of HIV infection or of the clinical symptoms of AIDS. The term "prophylaxis" includes a delay in contracting an HIV
- 20 infection or experiencing symptoms of HIV infection including the clinical symptoms of AIDS. Certain symptoms are shared between symptoms of an HIV infection, and the clinical symptoms of AIDS. As will be understood by one skilled in the art, examples of shared symptoms include a detectable viral load and reduced levels of CD4+ cells. Certain HIV infected individuals have a low viral load and fail to show the clinical symptoms of
- 25 AIDS such as immunosuppression, wasting diseases or increased levels of opportunistic infections. Accordingly, the vectors of the present invention are used to treat the symptoms of HIV infection and/or than the clinical symptoms of AIDS and AIDS related disorders.

- 30 Although human subjects are primarily contemplated, reference to a "subject" should be understood to include mammals including primates (eg, humans, monkeys), livestock

- 11 -

animals (eg, sheep, cows, horses, donkeys, goats, pigs), laboratory test animals (eg, mice, rats, ducks, dogs, guinea pigs, rabbits, hamsters), companion animals (eg, dogs, cats, birds), and captive wild animals (eg, kangaroos, deer, foxes). Preferably said subject is a mammal, more preferably a primate and even more preferably a human.

5

The phrase "modulatory factor" is used herein include to those host factors which act as chemical messengers between cells to effect change in response to external or internal stimuli. Thus ligands for cellular receptors such as cytokines, growth factors and chemokines are contemplated together with their functional homologs, parts, derivatives and analogs. As will be understood by those skilled in the art, the activity of such a factor may also be achieved through the administration of a compound which acts as an agonist of said factor or as an antagonist of inhibitors of the said factor or by down stream effectors in the same pathway or network. Accordingly, the term modulatory factors includes reference to the host factor, its down stream effectors and agonists thereof.

15

In a further embodiment, the present invention provides a recombinant poxvirus vector comprising a sequence of nucleotides encoding a retrovirus antigen and a sequence of nucleotides encoding a cytokine, or a functional homolog, derivative, part or analog thereof, which co-expresses said sequences for use in conjunction with ARDT in the treatment or prophylaxis of one or more symptoms associated with a retroviral infection in a subject.

In a particularly preferred embodiment, the modulatory factor of the present invention is selected from IFN $\gamma$ , IL-12, IL-2, TNF and IL-6 and down stream effectors and agonists thereof. IFN $\gamma$  is exemplified herein and IFN $\gamma$  or its functional homologs, parts, derivatives and analogs are preferred.

In a preferred, aspect the present invention provides a recombinant poxvirus vector comprising a sequence of nucleotides encoding a retrovirus antigen and a sequence of nucleotides encoding IFN $\gamma$ , or a functional homolog, derivative, part or analog thereof,

- 12 -

which co-expresses said constituents for use in conjunction with ARDT in the treatment or prophylaxis of one or more symptoms of a retroviral infection in a subject.

Preferred retroviral antigens include those encoded by a coding regions selected from *gag*,  
5 *env*, *pol* and *pro* coding regions.

Particularly preferred antigens are those encoded by *gag* and/or *pol* coding regions. A *gag/pol* construct is also preferred.

10 The present invention is particularly directed to the treatment of human retroviral infections such as HIV and preferably HIV-1.

In a particularly preferred embodiment the retroviral antigens are encoded by *gag* and *pol* coding regions derived from HIV and preferably HIV-1.

15

Accordingly, in another preferred aspect the present invention provides a recombinant poxvirus vector comprising a sequence of nucleotides encoding *gag* and/or *pol* antigens from HIV and a sequence of nucleotides encoding IFN $\gamma$ , or a functional homologue, derivative, part, or analogue thereof, which vector co-expresses said sequences for use in  
20 conjunction with ARDT in the treatment or prophylaxis of one or more symptoms of an HIV infection or AIDS in a subject.

Accordingly, in another aspect the present invention provides a recombinant poxvirus vector comprising a sequence of nucleotides encoding *gag* and *pol* antigens from HIV and  
25 a sequence of nucleotides encoding IFN $\gamma$ , or a functional homologue, derivative, part, or analogue thereof, which vector co-expresses said sequences for use in conjunction with ARDT in the treatment or prophylaxis of one or more symptoms of an HIV infection or AIDS in a subject.

30 Preferably said poxvirus is a fowlpox virus.

- 13 -

In a further embodiment the gag antigen is encoded or partially encoded by a sequence of nucleotides set forth in SEQ ID NO: 1 or a sequence of nucleotides having at least 60% similarity thereto after optimal alignment or a sequence which hybridises to a complementary form thereof under conditions of medium stringency.

5

In a further embodiment the pol antigen is encoded or partially encoded by a sequence of nucleotides set forth in SEQ ID NO: 1 or a sequence of nucleotides having at least 60% similarity thereto after optimal alignment or a sequence which hybridises to a complementary form thereof under conditions of medium stringency.

10

In a further embodiment the IFN $\gamma$  antigen is encoded or partially encoded by a sequence of nucleotides set forth in SEQ ID NO: 1 or a sequence of nucleotides having at least 60% similarity thereto or a sequence which hybridises to a complementary form thereof under conditions of medium stringency.

15

A "functional homolog" include species homologs whose function is conserved between species. Thus a functional homology of IFN $\gamma$  retains its modulatory function. A functional homolog of pol, for example, retains its antigenic or biochemical function.

20 A "functional derivative" of an antigen or modulatory factor encompasses variants and portions or a part of a full length polypeptide, which retains the functional activity of the parent molecule. Such, active fragments include deletion mutants and small peptides, for example, of at least 10, preferably at least 20 and more preferably at least 30 contiguous amino acids, which exhibit the requisite activity. Peptides of this type may be obtained  
25 through the application of standard recombinant nucleic acid techniques or synthesized using conventional liquid or solid phase synthesis as described in Chapter 9 entitled "Peptide Synthesis" by Atherton and Shephard which is included in a publication entitled "Synthetic Vaccines" edited by Nicholson and published by Blackwell Scientific Publications.

30

5

10

20

30



Functional derivatives of target molecules in nucleic acid form include nucleic acid molecules comprising a nucleotide sequence capable of hybridising to the target molecule or its complementary form under low stringency conditions.

Analogs contemplated herein include but are not limited to modification to side chains, incorporating of unnatural amino acids and/or their derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose conformational constraints on the proteinaceous molecule or their analogs.

Examples of side chain modifications contemplated by the present invention include modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with  $\text{NaBH}_4$ ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulphonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with  $\text{NaBH}_4$ .

The carboxyl group may be modified by carbodiimide activation via O-acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.

COMS ID No: SMBI-00454074 Received by IP Australia: Time (H:m) 16:59 Date (Y-M-d) 2003-10-15

- 16 -

Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline pH.

10 Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by  
15 alkylation with iodoacetic acid derivatives or N-carbethoxylation with  
diethylpyrocarbonate.

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 2.

P:\C920\2310\spec\Spec\Visa\1235500 HIV\4.4m-15/10/03

- 17 -

TABLE 2

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
5	$\alpha$ -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	$\alpha$ -amino- $\alpha$ -methylbutyrate	Mgab	L-N-methylarginine	Nmarg
	aminocyclopropane- carboxylate	Cpro	L-N-methylasparagine	Nmasn
			L-N-methylaspartic acid	Nmasp
10	aminoisobutyric acid	Aib	L-N-methylcysteine	Nmcys
	aminonorbornyl- carboxylate	Norb	L-N-methylglutamine	Nmgln
			L-N-methylglutamic acid	Nmglu
	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
15	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
20	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
25	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug
30	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva

- 18 -

	D-tyrosine	Dtyr	$\alpha$ -methyl-aminoisobutyrate	Maib
	D-valine	Dval	$\alpha$ -methyl- $\gamma$ -aminobutyrate	Mgabv
	D- $\alpha$ -methylalanine	Dmala	$\alpha$ -methylcyclohexylalanine	Mchexa
	D- $\alpha$ -methylarginine	Dmarg	$\alpha$ -methylcyclopentylalanine	Mcpen
5	D- $\alpha$ -methylasparagine	Dmasn	$\alpha$ -methyl- $\alpha$ -naphthylalanine	Manap
	D- $\alpha$ -methylaspartate	Dmasp	$\alpha$ -methylpenicillamine	Mpen
	D- $\alpha$ -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
	D- $\alpha$ -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- $\alpha$ -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Nom
10	D- $\alpha$ -methylisoleucine	Dmile	N-amino- $\alpha$ -methylbutyrate	Nmaabu
	D- $\alpha$ -methylleucine	Dmleu	$\alpha$ -naphthylalanine	Anap
	D- $\alpha$ -methyllysine	Dmlys	N-benzylglycine	Nphe
	D- $\alpha$ -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- $\alpha$ -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
15	D- $\alpha$ -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- $\alpha$ -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- $\alpha$ -methylserine	Dmser	N-cyclobutylglycine	Ncbut
	D- $\alpha$ -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- $\alpha$ -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
20	D- $\alpha$ -methyltyrosine	Dmty	N-cyclodecylglycine	Nedec
	D- $\alpha$ -methylvaline	Dmval	N-cyclododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
25	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr
	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
30	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis

COMS ID No: SMBI-00454074 Received by IP Australia: Time (H:m) 16:59 Date (Y-M-d) 2003-10-15

- 20 -

1-carboxy-1-(2,2-diphenyl-Nmbc  
ethylamino)cyclopropane

---

5 Crosslinkers can be used, for example, to stabilize 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having  $(CH_2)_n$  spacer groups with  $n=1$  to  $n=6$ , glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or  
10 carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of  $C_\alpha$  and N  $\alpha$ -methylamino acids, introduction of double bonds between  $C_\alpha$  and  $C_\beta$  atoms of amino acids and the formation of cyclic peptides or analogues by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

15

These types of molecules may be important to stabilise vector constructs or their expressed products.

The terms "similarity" or "identity" as used herein include exact identity between  
20 compared sequences at the nucleotide or amino acid level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which result in different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. Where there is non-identity at the amino acid level, "similarity" includes amino acids that are nevertheless related to each other at the  
25 structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, nucleotide and amino acid sequence comparisons are made at the level of identity rather than similarity.

Terms used to describe sequence relationships between two or more polynucleotides or  
30 polypeptides include "reference sequence", "comparison window", "sequence similarity", "sequence identity", "percentage of sequence similarity", "percentage of sequence

- 21 -

identity", "substantially similar" and "substantial identity". A "reference sequence" is at least 12 but frequently 15 to 18 and often at least 25 or above, such as 30 monomer units, inclusive of nucleotides and amino acid residues, in length. Because two polynucleotides may each comprise (1) a sequence (i.e. only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window" refers to a conceptual segment of typically 12 contiguous residues that is compared to a reference sequence. The comparison window may comprise additions or deletions (i.e. gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison window may be conducted by computerised implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also may be made to the BLAST family of programs as, for example, disclosed by Altschul *et al.* (*Nucl. Acids Res.* 25: 3389, 1997). A detailed discussion of sequence analysis can be found in Unit 19.3 of Ausubel *et al.* ("Current Protocols in Molecular Biology" John Wiley & Sons Inc, 1994-1998, Chapter 15).

The terms "sequence similarity" and "sequence identity" as used herein refer to the extent that sequences are identical or functionally or structurally similar on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a "percentage of sequence identity", for example, is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g. A, T, C, G, I) or the identical amino acid residue (e.g. Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched

PROTEINEXTRACT: 13351720 FIVE: 1371003

- 22 -

- positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, "sequence identity" will be understood to mean the "match percentage" calculated by the DNASIS computer program (Version 2.5 for windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software. Similar comments apply in relation to sequence similarity.
- 10 Preferably, the percentage similarity between a particular sequence and a reference sequence (nucleotide or amino acid) is at least about 60% or at least about 70% or at least about 80% or at least about 90% or at least about 95% or above such as at least about 96%, 97%, 98%, 99% or greater. Percentage similarities or identities between 60% and 100% are also contemplated such as 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100%.

- Reference herein to a low stringency includes and encompasses from at least about 0 to at least about 15% v/v formamide and from at least about 1 M to at least about 2 M salt for hybridization, and at least about 1 M to at least about 2 M salt for washing conditions. Generally, low stringency is at from about 25-30°C to about 42°C. The temperature may be altered and higher temperatures used to replace formamide and/or to give alternative stringency conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5 M to at least about 0.9 M salt for hybridization, and at least about 0.5 M to at least about 0.9 M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01 M to at least about 0.15 M salt for hybridization, and at least about 0.01 M to at least about 0.15 M salt for washing conditions. In general, washing is carried out  $T_m = 69.3 + 0.41 (G+C)\%$  (Marmur and Doty, *J. Mol. Biol.* 5: 109, 1962). However, the  $T_m$  of a duplex DNA decreases by 1°C



- 23 -

with every increase of 1% in the number of mismatch base pairs (Bonner and Laskey, *Eur. J. Biochem.* 46: 83, 1974). Formamide is optional in these hybridization conditions. Accordingly, particularly preferred levels of stringency are defined as follows: low stringency is 6 x SSC buffer, 0.1% w/v SDS at 25-42°C; a moderate stringency is 2 x SSC buffer, 0.1% w/v SDS at a temperature in the range 20°C to 65°C; high stringency is 0.1 x SSC buffer, 0.1% w/v SDS at a temperature of at least 65°C.

The present invention contemplates expression of the nucleotide sequences encoding the modulatory factor and/or the retroviral antigen in recipient cells. However, appropriate alternative means to deliver said agents to recipient cells may be practiced within the scope of the present invention. Thus, the modulatory factor may be administered in proteinaceous or other suitable and pharmaceutically acceptable chemical form optionally in conjunction with the vector of the present invention comprising a nucleotide sequence encoding a retroviral antigen and/or said modulatory factor.

In another aspect the present invention provides a pharmaceutical composition comprising any one of the above-described vectors together with a pharmaceutically acceptable carrier and/or diluent for use in conjunction with ARDT in the treatment or prevention of a retroviral infection.

The term pharmaceutical composition is used herein to refer to a chemical compound which induces a desired pharmacological and/or physiological effect. The term encompasses pharmaceutically acceptable and pharmacologically active ingredients of the active agent and includes pharmaceutically acceptable and pharmacologically active salts, esters, amides, pro-forms, metabolites, analogues, etc. The term "compound" as used herein is not to be construed as a chemical molecule only but extends to peptides, polypeptides, and proteins as well as nucleic acid molecules and chemical analogues thereof.

By "pharmaceutically acceptable" excipient or diluent is meant a pharmaceutical vehicle comprised of material which is not biologically or otherwise undesirable, ie the material

5 In a preferred aspect said pharmaceutical composition is useful in conjunction with anti-retroviral drug treatment to modulate viral load in a subject.

15 In another aspect, the present invention contemplates a recombinant vector comprising a sequence of nucleotides encoding a retroviral antigen and a sequence of nucleotides encoding a cytokine or a functional homolog, part, derivative or analog thereof, wherein upon administration to a subject carrying a low retroviral load, said nucleotide sequences are expressed in target cells and said low viral load is effectively maintained or prolonged.

Viral load is measured in terms of the number of viral particles/ml of plasma and is a useful and direct measure of viral infection and a surrogate marker of efficacy in retroviral treatment regimens including drug treatments and immunisation protocols. In particular, anti-retroviral drug treatment is usually started in a patient when their viral load goes above or is maintained above about 50 viral particles/ml of plasma for an appropriate period of time. One of the consequences of stopping or interrupting anti-retroviral drug treatment is that the viral load may "rebound" to a level which is as high or higher than the level before treatment commenced. Such viral rebound when left untreated is associated

- 25 -

with the progression in a subject to development of the symptoms of primary HIV infection or the clinical symptoms of AIDS, or a worsening thereof. Accordingly, another useful measure of the efficacy of a treatment regimen in a subject is the time to development of detectable plasma viral loads or the time to re-initiation of anti-retroviral drug treatment. As absolute viral numbers as well as relative numbers are diagnostic it is also useful to consider the maximum viral load in a subject as well as the time-weighted change from a baseline value over a treatment period or during a post- or inter-treatment period. The protocols used to measure and quantify plasma viral loads are well known in the art and typically employ RT-PCR.

10

Another measure of treatment success or clinical progression is the ratio of CD4:CD8 T-cells in a subject. Furthermore, the success of immunization strategies and a measure of the immune status of a subject may be gauged by measuring CD8 T-cell responses and/or antibody responses to specific antigens. Methods of determining the cellular, virological and immunological status of a subject are well known in the art and are, for example, described in Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1998, and references cited therein.

15

A low viral load is an average figure and is preferably less than an average over time of about 50,000 copies/ml plasma. Preferably the average low viral load is less than about 40,000 copies/ml, more preferably less than about 30,000 copies/ml, still more preferably less than about 20,000 copies/ml, still more preferably less than about 10,000 copies/ml, even still more preferably less than about 1000 copies/ml, or any number between these aforementioned figures or between 1000 and 0 or undetectable copies /ml such as between 1000 and 100 copies/ml, between 500 and 50 copies/ml, or between 750 and 80 copies/ml, etc. Most preferably a low viral load is below 50 copies/ml.

20

The delay in viral rebound or a delay in an increase in viral load is any time frame which is likely to convey clinical benefit and may be measured in days, weeks, months or years. As exemplified herein, the average maximum viral load for subjects receiving the full

25

30

POF2ABINpoc\Store\Work\1212520 FPV\en\doc&gt;15/10/03

- 26 -

construct (FC) was about 20,000 copies/ml and this was monitored over the 20 weeks of the study during withdrawal from anti-retroviral therapy.

Poxvirus vectors are particularly convenient vectors. Preferred poxvirus vectors are avipox or orthopox vectors which do not replicate efficiently in human subjects. A particularly preferred poxvirus vector is a fowlpox vector (FPV). Exemplary fowlpox vectors are FPV-M3 vectors as described in International Patent Publication No. WO 00/28003.

10 In a particularly preferred embodiment, the cytokine is selected from IFN $\gamma$ , IL-12, IL-2, TNF and IL-6 and down stream effectors and agonists thereof. IFN $\gamma$  is exemplified herein and IFN $\gamma$  or its functional homologs, parts, derivatives and analogs are preferred.

Preferred retroviral antigens include those encoded by a coding regions selected from *gag*,  
15 *env*, *pol* and *pro* coding regions.

Particularly preferred antigens are those encoded by *gag* and/or *pol* coding regions. A *gag/pol* construct is also preferred.

20 The preferred retrovirus is HIV-1.

In a further embodiment, the recombinant vector of the present invention is administered in conjunction with ARDT. By "in conjunction" is meant that the instant vector and ARDT are used together but not necessarily simultaneously in order to improve treatment  
25 efficacy. In accordance with the present invention treatment efficacy is improved by providing an alternative or additional treatment to ARDT wherein the deleterious side effects of ARDT are reduced. Specifically, administration of the instant vector permits a treatment protocol to be conducted in which anti-retroviral drugs may be taken  
intermittently,

30

- 27 -

Accordingly, the present invention provides a recombinant vector comprising a sequence of nucleotides encoding a retroviral antigen and a sequence of nucleotides encoding a cytokine or a functional homolog, part, derivative or analogue thereof, wherein upon administration to a subject carrying a low retroviral load as a result of ARDT, said antigens  
5 are expressed in target cells and said low viral load is effectively maintained or prolonged after or while ARDT is withdrawn.

**For the avoidance of doubt, the instant vector may be administered before, during, after or between ARDT/s.**

10

In a preferred aspect, the present invention provides a method of treatment or prophylaxis comprising the administration of a vector comprising a sequence of nucleotides encoding a retroviral antigen and/or a sequence of nucleotides encoding a cytokine or a functional homolog, part, derivative or analogue thereof in conjunction with ARDT wherein said method is effective in maintaining a low retroviral load in a subject or reducing or delaying viral rebound in said subject.

**In a preferred aspect, administration of the instant vector effectively prevents or treats one or more of the symptoms of HIV infection or AIDS.**

20

In another aspect the present invention provides a method of treatment or prophylaxis comprising the administration of a vector comprising a sequence of nucleotides encoding a retroviral antigen and a sequence of nucleotides encoding a cytokine or a functional homolog, part, derivative or analog thereof in conjunction with ARDT wherein said method is effective in maintaining a low retroviral load in a subject or reducing or delaying viral rebound in a subject.

**In a preferred aspect administration of the instant vectors effectively prevents or treats one or more of the symptoms of HIV infection or AIDS.**

30

- 28 -

In a related aspect, the present invention provides a method of treatment or prophylaxis of AIDS comprising the administration of a vector comprising a sequence of nucleotides encoding a retroviral antigen and a sequence of nucleotides encoding a cytokine or a functional homolog, part, derivative or analogue thereof in conjunction with ARDT wherein said method is effective in maintaining a low retroviral load in a subject or reducing or delaying viral rebound in the absence of ARDT.

To be "effective" an "effective amount" of the instant vector is administered. As used herein an effective amount mean a sufficient amount of the vector to provide the desired therapeutic or physiological outcome. Undesirable effects, e.g. side effects, are sometimes manifested along with the desired therapeutic effect; hence, a practitioner balances the potential benefits against the potential risks in determining what is an appropriate "effective amount". The exact amount and frequency of administration required will vary from subject to subject, depending on the species, age and general clinical condition of the subject, mode of administration and the like. Thus, it may not be possible to specify an exact "effective amount". However, an appropriate "effective amount" in any individual case may be determined by one of ordinary skill in the art using only routine experimentation.

The molecules of the present invention can be formulated in pharmaceutical compositions which are prepared according to conventional pharmaceutical compounding techniques. See, for example, Remington's Pharmaceutical Sciences, 18<sup>th</sup> Ed. (1990, Mack Publishing, Company, Easton, PA, U.S.A.). The composition may contain the active agent or pharmaceutically acceptable salts of the active agent. These compositions may comprise, in addition to one of the active substances, a pharmaceutically acceptable excipient, carrier, buffer, stabilizer or other materials well known in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. intravenous, oral, intrathecal, epineural or parenteral. Intramuscular administration is preferred.

- 29 -

For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, powders, suspensions or emulsions. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, suspending agents, and the like in the case of oral liquid preparations (such as, for example, suspensions, elixirs and solutions); or carriers such as starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations (such as, for example, powders, capsules and tablets). Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar-coated or enteric-coated by standard techniques. The active agent can be encapsulated to make it stable to passage through the gastrointestinal tract while at the same time allowing for passage across the blood brain barrier. See for example, International Patent Publication No. WO 96/11698.

15

For parenteral administration, the compound may be dissolved in a pharmaceutical carrier and administered as either a solution or a suspension. Illustrative of suitable carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative or synthetic origin. The carrier may also contain other ingredients, for example, preservatives, suspending agents, solubilizing agents, buffers and the like. When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid.

20

The active agent is preferably administered in a therapeutically effective amount. The actual amount administered and the rate and time-course of administration will depend on the nature and severity of the condition being treated. Prescription of treatment, e.g. decisions on dosage, timing, etc. is within the responsibility of general practitioners or specialists and typically takes account of the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners. Examples of techniques and protocols can be found in Remington's Pharmaceutical Sciences, *supra*.

30

- 30 -

Alternatively, targeting therapies may be used to deliver the active agent more specifically to certain types of cell, by the use of targeting systems such as antibodies or cell specific ligands. Targeting may be desirable for a variety of reasons, e.g. if the agent is unacceptably toxic or if it would otherwise require too high a dosage or if it would not  
5 otherwise be able to enter the desired cells.

Cell based delivery system may be employed such as described in U.S. Patent No. 5,550,050 and International Patent Publication Nos. WO 92/19195, WO 94/25503, WO 95/01203, WO 95/05452, WO 96/02286, WO 96/02646, WO 96/40871, WO 96/40959 and  
10 WO 97/12635. The vector could be targeted to cells harbouring latent infection or expression of expression products could be limited to specific cells, stages of development or cell cycle stages. The cell based delivery system is designed to be implanted in a patient's body at the desired site. Alternatively, the agent could be administered in a precursor form for conversion to the active form by an activating agent produced in, or  
15 targeted to, the cells to be treated. See, for example, European Patent Application No. 0 425 731A and International Patent Publication No. WO 90/07936.

In another aspect, the present invention provides a method of reducing or alleviating one or more of the side effects of ARDT comprising the administration to a subject of a vector  
20 comprising a sequence of nucleotides encoding a retroviral antigen and/or a sequence of nucleotides encoding a cytokine, or a functional derivative, homolog, part or analog thereof, for a time and under conditions sufficient to co-express said sequences and to reduce or alleviate one or more of the side effects of ARDT.

25 In a further aspect, the present invention provides a method of reducing or alleviating one or more of the side effects of ARDT comprising the administration to a subject of a vector comprising a sequence of nucleotides encoding a retroviral antigen and a sequence of nucleotides encoding a cytokine, or a functional derivative, homolog, part or analog thereof, for a time and under conditions sufficient to co-express said sequences and to  
30 reduce or alleviate one or more of the side effects of ARDT.



Preferably, said vector is a poxvirus vector. More preferable an avipox vector. Still more preferably a fowlpox vector.

Preferably the retroviral antigen is *gag* and/or *pol*. Most preferably HIV *gag/pol* is employed.

The side effects of ARDT are numerous and are well known in the art and include, without limitation, nausea, vomiting, fever fat redistribution, heart disease, liver disease and insulin resistance. Treatment and prophylaxis regimens are tailored to the individual and include priming and/or boosting with the vector before or during ARDT or after withdrawal ARDT and before or after re-initiation of ARDT. ARDT may be withdrawn for a period of time ranging from days to several months depending on the level and extent of side effects experienced by a recipient and the vector may be administered in prime and/or boost format during this period to maintain low level of viral load.

COMS ID No: SMBI-00454074 Received by IP Australia: Time (H:m) 16:59 Date (Y-M-d) 2003-10-15

- 32 -

In a related aspect the present invention extends to the use of the subject vectors in the manufacture of a medicament for use in conjunction with ARDT in the treatment or prophylaxis of a retroviral infection and symptoms associated therewith.

- 5 In one aspect, the present invention broadly contemplates the use of a vector comprising a sequence of nucleotides encoding a retroviral antigen and/or a sequence of nucleotides encoding a cytokine or a functional derivative, homolog, part or analog thereof in the manufacture of a medicament for use in a method of reducing or alleviating one or more of the side effects of ARDT.

10

Preferably the subject has previously been treated with an anti-retroviral compound. The instant vectors may be administering before or during ARDT or after withdrawal of ARDT. When administered before or during ARDT, ARDT may subsequently be withdrawn and in accordance with the present invention, viral loads are maintained at a

- 15 low level in the absence of ARDT.

In accordance with this aspect of the invention, preferably, said vector is a poxvirus vector. More preferably an avipox vector. Still more preferably a fowlpox vector.

- 20 In a further preferred embodiment the cytokine is interferon- $\gamma$ . Preferably the retroviral antigen is gag and/or pol. Most preferably HIV gag/pol are employed.

- Accordingly, in a preferred embodiment, the present invention provides the use of a fowlpox vector comprising a sequence of nucleotides encoding HIV gag/pol and a  
25 sequence of nucleotides encoding interferon- $\gamma$  or a functional derivative, homolog, part or analog thereof in the manufacture of a medicament for use in a method of reducing or alleviating one or more of the side effects of ARDT.

- Said medicament is conveniently in a format for administration as a priming dose and/or a  
30 boosting dose. A broad range of doses may be applicable. For example, a unit dose may comprise from about  $1 \times 10^6$  PFU per ml to about  $1 \times 10^8$  PFU per ml. Dosage regimens

- 33 -

are adjusted to provide the optimum therapeutic dose and priming administrations may be administered daily, weekly or monthly or at other suitable time intervals or may be proportionately reduced as indicated by the exigencies of the situation. A preferred priming dose is  $5 \times 10^7$  PFU per ml in one ml of diluent. Boosting doses may be the same as priming doses or they may be more or less concentrated as indicated by the exigencies of the situation. For other constructs, from about 0.1  $\mu$ g to 1 mg of vector may be administered per kilogram of body weight per day.

**The present invention is further described by the following non-limiting Examples.**

10

- 34 -

**EXAMPLE 1****Randomised, Placebo-controlled, Phase I/IIa Evaluation of the Safety and Biological Activity of Avipox Virus Expressing HIV gag-pol and Interferon-gamma in HIV-1 Infected Subjects.**

5

A clinical trial was conducted to establish the safety and immunogenicity of recombinant fowlpox virus vaccines (rFPV) expressing HIV gag-pol or co-expressing HIV gag/pol and human interferon-gamma (IFN $\gamma$ ) in HIV positive subjects taking combination anti-retroviral drug therapy (ART). A total of 34 patients completed the trial in which they received a series of injections and blood tests regularly over six months. Patients continued to take standard anti-retroviral therapies throughout the trial period. As announced on 17 February, 2003 (virax.com.au) the data for this trial indicated that neither construct elicited a specific immune response in trial participants receiving ART.

15

**EXAMPLE 2****Safety, Biological Activity and Extension Study to Assess The Anti-retrovirological Properties of a Therapeutic HIV Vaccine Candidate Based on Recombinant Fowlpox Virus (rFPV).**

20

A multicentre, randomised, double-blind, placebo-controlled trial recruited HIV-infected individuals treated with anti-retroviral therapy (ART) during primary HIV infection, who maintained control of virus replication (plasma viral load < 50 copies/mL) since initiation of ART. Subjects were randomised to one of three study arms: diluent alone (placebo), rFPV expressing HIV gag/pol (partial construct - PC) or rFPV expressing HIV gag/pol and IFN- $\gamma$  (full construct - FC). Vaccines were administered by intramuscular injection on day 0, week 4 and week 12 at a unit dose of  $5 \times 10^7$  pfu/mL in 1.0mL of diluent. Follow-up continued over 52 weeks. Primary endpoints were mean change in CD8+ effector function

25  
30

- 35 -

as determined by CTL response or ELISPOT assay from baseline to week 26 and increase in log viral load from baseline to week 52. Analyses of safety endpoints was according to treatment received. All analyses were performed using "intention to treat" methods.

- 5 In this trial, 35 eligible subjects were randomised (12 placebo, 11 PC-rFPV, 12 FC-rFPV). All but one subject (placebo group) received all three immunisations. All 35 subjects completed 52 weeks of follow-up. No significant toxicity or safety concerns were observed during the study. Episodes of detectable HIV viremia (eight episodes in five patients) were infrequent across the 52 weeks of study and there was no difference between vaccine
- 10 groups. There were no significant differences between the combined PC and FC groups with placebo patients for anti-HIV gag ELISPOT responses (time-weighted mean difference in change from baseline = -56 sfu/106 PBMC;  $p = 0.062$ ), anti-HIV p55 lymphoproliferative responses (time-weighted mean difference in change from baseline =
- 15 4.4 SI;  $p = 0.337$ ), anti-HIV gag lymphoproliferative responses (time-weighted mean difference in change from baseline = 2.1 SI;  $p = 0.778$ ). No additional anti-HIV antibody responses were observed during follow-up. Western Blot reactive anti-FPV antibodies were detected in all PC and FC recipients at week 6 and persisted for the duration of the study. Vaccine recipients generated long-lasting reactive anti-FPV antibodies soon after administration of candidate vaccines.
- 20 A pilot multicentre, double-blind, placebo-controlled 20-week extension of the study was conducted to examine the effect of immunisation with recombinant fowlpox virus vaccines (rFPV) on measures of HIV replication following cessation of combination antiretroviral therapy (ART). Previously enrolled individuals protocol were re-consented on day 0, prior
- 25 to receiving a boosting vaccination by intramuscular injection in accordance with their original randomised assignment: diluent alone (placebo), rFPV expressing HIV gag/pol (partial construct - PC) or rFPV expressing HIV gag/pol and interferon-gamma (full construct - FC). All ART was ceased one week following immunisation. Virological and immunological monitoring was monitored frequently for 20 weeks after immunisation. The
- 30 primary endpoint was time-weighted area under the curve change from plasma HIV-RNA VL (pVL) at baseline until reintroduction of ART. Secondary endpoints included log pVL

- 36 -

after cessation of ART (post-vaccination pVL set-point), kinetics and rate of pVL recrudescence, median time to reinitiation of ART, CD8+ T-cell responses to HIV antigens and CD4+/CD8+ T-cell count changes.

- 5 Twenty-five (71%) of the original study cohort consented to participate (placebo = 7; PC = 8; FC = 10). Antiretroviral therapy was re-introduced in 7 patients (placebo = 3; PC = 3; FC = 1). Immunisations were well-tolerated. One patient (PC group) experienced a transient grade 3 thrombocytopenia that resolved without treatment. The time weighted mean change from baseline pVL over 20 weeks was 1.80 (0.72), 1.78 (0.91) and 0.96 (0.91) for placebo, PC and FC respectively ( $p = 0.253$ , when comparing FC and PC recipients to placebo). The time-weighted mean change from baseline CD4+ cell count was -90.7 (210.1), 2.05 (166.3) and 3.45 (160.9) for placebo, PC and FC respectively ( $p = 0.238$ , when comparing FC and PC recipients to placebo). All patients had at least one detectable pVL ( $>50$  copies/mL) during follow-up. FC and PC recipients compared to placebo had similar times to detectable pVL (hazard ratio 1.21, 95% CI 0.40 – 2.97,  $p = 0.682$ ). Time to reinitiation of ART was not statistically significantly different in FC and PC recipients compared to placebo (hazard ratio = 2.08, 95% CI 0.49 – 9.31,  $p = 0.338$ ).

- Recipients of the Full construct (FC) rFPV immunization experienced a log reduction in pVL compared to recipients of the PC rFPV or placebo. Specifically, the average maximum viral loads for each of the groups was as follows: placebo group-67173 copies/ml; partial construct group-68841; and full construct group-18897 (see Figure 1). Unexpectedly therefore, notwithstanding the lack of any demonstrable immune response in the early part of the trial, in the absence of ARDT, administration of the vector resulted in an approximately 10 fold reduction in average viral load and therapeutic effect over the 20 week period of the study. As specified above, retroviral therapy was re-introduced in a total of seven patients, the seven comprising three from the placebo group, three from the group receiving the partial construct and only one from the largest group receiving the full construct as shown in Figure 2.

30

P:\PUBS\Rep\Chen\HIV\02211926 HIV\Lab-157103

- 37 -

**BIBLIOGRAPHY**

- Altschul *et al.*, *Nucl. Acids Res.*, 25:3389, 1997.
- 5 Australian Society for HIV Medicine (ASHM)-2001, Australian Antiretroviral Guidelines, <http://www.ashm.org.au>.
- Ausubel *et al.*, "Current Protocols in Molecular Biology" John Wiley & Sons Inc, 1994-1998, Chapter 15.
- 10 Bonner, *et al.*, *Eur. J. Biochem.*, 46:83, 1974.
- Harlow and Larc, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1998.
- 15 Marmur, *et al.*, *J. Mol. Biol.*, 5:109, 1962.
- Melors J.W. *et al.*, *Science* 272:1167-1170, 1996.
- 20 Paul, *Fundamental Immunology*, 3<sup>rd</sup> Ed., 243-247 (Raven Press, 1993).
- Vogt P.K., Chapter 1 In: *Retroviruses*, Coffin, J. M.; Hughes, S. H. and Varmus, H. E. (eds.), Cold Spring Harbor Laboratory Press, USA, 1997.

1/2




Figure 1



2/2




FIGURE 2

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/AU04/001423

International filing date: 15 October 2004 (15.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: AU  
Number: 2003905642  
Filing date: 15 October 2003 (15.10.2003)

Date of receipt at the International Bureau: 08 November 2004 (08.11.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record.**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**